Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.

Kelly PN, Romero DL, Yang Y, Shaffer AL 3rd, Chaudhary D, Robinson S, Miao W, Rui L, Westlin WF, Kapeller R, Staudt LM.

J Exp Med. 2015 Dec 14;212(13):2189-201. doi: 10.1084/jem.20151074. Epub 2015 Nov 30.

2.

Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field.

Wang L, Wu Y, Deng Y, Kim B, Pierce L, Krilov G, Lupyan D, Robinson S, Dahlgren MK, Greenwood J, Romero DL, Masse C, Knight JL, Steinbrecher T, Beuming T, Damm W, Harder E, Sherman W, Brewer M, Wester R, Murcko M, Frye L, Farid R, Lin T, Mobley DL, Jorgensen WL, Berne BJ, Friesner RA, Abel R.

J Am Chem Soc. 2015 Feb 25;137(7):2695-703. doi: 10.1021/ja512751q. Epub 2015 Feb 12.

PMID:
25625324
3.

Recent advances in the discovery of small molecule inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4) as a therapeutic target for inflammation and oncology disorders.

Chaudhary D, Robinson S, Romero DL.

J Med Chem. 2015 Jan 8;58(1):96-110. doi: 10.1021/jm5016044. Epub 2014 Dec 5. Review.

PMID:
25479567
4.

Current HIV therapeutics: mechanistic and chemical determinants of toxicity.

Chiao SK, Romero DL, Johnson DE.

Curr Opin Drug Discov Devel. 2009 Jan;12(1):53-60. Review.

PMID:
19152213
5.

Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics.

Stiff C, Graber DR, Thorarensen A, Wakefield BD, Marotti KR, Melchior EP, Sweeney MT, Han F, Rohrer DC, Zurenko GE, Romero DL.

Bioorg Med Chem Lett. 2008 Dec 1;18(23):6293-7. doi: 10.1016/j.bmcl.2007.08.041. Epub 2007 Aug 25.

PMID:
18951783
6.

Resistance mapping and mode of action of a novel class of antibacterial anthranilic acids: evidence for disruption of cell wall biosynthesis.

Mott JE, Shaw BA, Smith JF, Bonin PD, Romero DL, Marotti KR, Miller AA.

J Antimicrob Chemother. 2008 Oct;62(4):720-9. doi: 10.1093/jac/dkn261. Epub 2008 Jun 19.

PMID:
18567575
7.

Correlation of carboxylic acid pKa to protein binding and antibacterial activity of a novel class of bacterial translation inhibitors.

Stiff CM, Zhong M, Sarver RW, Gao H, Ho AM, Sweeney MT, Zurenko GE, Romero DL.

Bioorg Med Chem Lett. 2007 Oct 1;17(19):5479-82. Epub 2007 May 10.

PMID:
17709248
8.

Structure-activity relationships of bioisosteres of a carboxylic acid in a novel class of bacterial translation inhibitors.

Ruble JC, Wakefield BD, Kamilar GM, Marotti KR, Melchior E, Sweeney MT, Zurenko GE, Romero DL.

Bioorg Med Chem Lett. 2007 Jul 15;17(14):4040-3. Epub 2007 Apr 27.

PMID:
17561394
9.

Human serum albumin binding assay based on displacement of a non selective fluorescent inhibitor.

Thorarensen A, Sarver RW, Tian F, Ho A, Romero DL, Marotti KR.

Bioorg Med Chem Lett. 2007 Aug 15;17(16):4646-9. Epub 2007 May 27.

PMID:
17560104
10.

Preparation of novel anthranilic acids as antibacterial agents: extensive evaluation of structural and physical properties on antibacterial activity and human serum albumin affinity.

Thorarensen A, Li J, Wakefield BD, Romero DL, Marotti KR, Sweeney MT, Zurenko GE, Sarver RW.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3113-6. Epub 2007 Mar 15.

PMID:
17400450
11.

Preparation of novel anthranilic acids as antibacterial agents. Extensive evaluation of alternative amide bioisosteres connecting the A- and the B-rings.

Thorarensen A, Wakefield BD, Romero DL, Marotti KR, Sweeney MT, Zurenko GE, Rohrer DC, Han F, Bryant GL Jr.

Bioorg Med Chem Lett. 2007 May 15;17(10):2823-7. Epub 2007 Feb 25.

PMID:
17368020
12.

Preparation of novel antibacterial agents. Replacement of the central aromatic ring with heterocycles.

Li J, Wakefield BD, Ruble JC, Stiff CM, Romero DL, Marotti KR, Sweeney MT, Zurenko GE, Rohrer DC, Thorarensen A.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2347-50. Epub 2006 Dec 21.

PMID:
17350254
13.

Discovery and initial development of a novel class of antibacterials: inhibitors of Staphylococcus aureus transcription/translation.

Larsen SD, Hester MR, Craig Ruble J, Kamilar GM, Romero DL, Wakefield B, Melchior EP, Sweeney MT, Marotti KR.

Bioorg Med Chem Lett. 2006 Dec 15;16(24):6173-7. Epub 2006 Oct 5.

PMID:
17027262
14.
15.

Asymmetric Synthesis of the C3alpha Fragment of 5,6-Dihydro-alpha-pyrone Nonpeptidic HIV-1 Protease Inhibitors.

Romero DL, Manninen PR, Han F, Romero AG.

J Org Chem. 1999 Jun 25;64(13):4980-4984. No abstract available.

PMID:
11674587
16.

The solid phase synthesis of tetrahydroisoquinolines having cdc25B inhibitory activity.

Fritzen EL, Brightwell AS, Erickson LA, Romero DL.

Bioorg Med Chem Lett. 2000 Apr 3;10(7):649-52.

PMID:
10762045
17.
18.

Synthesis and structure-activity relationships of the (alkylamino)piperidine-containing BHAP class of non-nucleoside reverse transcriptase inhibitors: effect of 3-alkylpyridine ring substitution.

Genin MJ, Poel TJ, May PD, Kopta LA, Yagi Y, Olmsted RA, Friis JM, Voorman RL, Adams WJ, Thomas RC, Romero DL.

J Med Chem. 1999 Oct 7;42(20):4140-9.

PMID:
10514284
19.

Discovery and development of the BHAP nonnucleoside reverse transcriptase inhibitor delavirdine mesylate.

Adams WJ, Aristoff PA, Jensen RK, Morozowich W, Romero DL, Schinzer WC, Tarpley WG, Thomas RC.

Pharm Biotechnol. 1998;11:285-312. Review. No abstract available.

PMID:
9760685
20.

Depletion of glutathione by benzo(a)pyrene metabolites, ionomycin, thapsigargin, and phorbol myristate in human peripheral blood mononuclear cells.

Romero DL, Mounho BJ, Lauer FT, Born JL, Burchiel SW.

Toxicol Appl Pharmacol. 1997 May;144(1):62-9.

PMID:
9169070
21.

Synthesis and bioactivity of novel bis(heteroaryl)piperazine (BHAP) reverse transcriptase inhibitors: structure-activity relationships and increased metabolic stability of novel substituted pyridine analogs.

Genin MJ, Poel TJ, Yagi Y, Biles C, Althaus I, Keiser BJ, Kopta LA, Friis JM, Reusser F, Adams WJ, Olmsted RA, Voorman RL, Thomas RC, Romero DL.

J Med Chem. 1996 Dec 20;39(26):5267-75.

PMID:
8978855
22.

Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.

Thaisrivongs S, Romero DL, Tommasi RA, Janakiraman MN, Strohbach JW, Turner SR, Biles C, Morge RR, Johnson PD, Aristoff PA, Tomich PK, Lynn JC, Horng MM, Chong KT, Hinshaw RR, Howe WJ, Finzel BC, Watenpaugh KD.

J Med Chem. 1996 Nov 8;39(23):4630-42.

PMID:
8917652
23.

Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.

Romero DL, Olmsted RA, Poel TJ, Morge RA, Biles C, Keiser BJ, Kopta LA, Friis JM, Hosley JD, Stefanski KJ, Wishka DG, Evans DB, Morris J, Stehle RG, Sharma SK, Yagi Y, Voorman RL, Adams WJ, Tarpley WG, Thomas RC.

J Med Chem. 1996 Sep 13;39(19):3769-89.

PMID:
8809165
25.
26.

The benzylthio-pyrimidine U-31,355, a potent inhibitor of HIV-1 reverse transcriptase.

Althaus IW, Chou KC, Lemay RJ, Franks KM, Deibel MR, Kezdy FJ, Resnick L, Busso ME, So AG, Downey KM, Romero DL, Thomas RC, Aristoff PA, Tarpley WG, Reusser F.

Biochem Pharmacol. 1996 Mar 22;51(6):743-50.

PMID:
8602869
27.

Kinetic studies with the non-nucleoside human immunodeficiency virus type-1 reverse transcriptase inhibitor U-90152E.

Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, Romero DL, Thomas RC, Aristoff PA, Tarpley WG, et al.

Biochem Pharmacol. 1994 Jun 1;47(11):2017-28.

PMID:
7516658
28.

Discovery, synthesis, and bioactivity of bis(heteroaryl)piperazines. 1. A novel class of non-nucleoside HIV-1 reverse transcriptase inhibitors.

Romero DL, Morge RA, Biles C, Berrios-Pena N, May PD, Palmer JR, Johnson PD, Smith HW, Busso M, Tan CK, et al.

J Med Chem. 1994 Apr 1;37(7):999-1014.

PMID:
7512142
29.

Steady-state kinetic studies with the polysulfonate U-9843, an HIV reverse transcriptase inhibitor.

Althaus IW, Chou JJ, Gonzales AJ, LeMay RJ, Deibel MR, Chou KC, Kezdy FJ, Romero DL, Thomas RC, Aristoff PA, et al.

Experientia. 1994 Jan 15;50(1):23-8.

30.

The quinoline U-78036 is a potent inhibitor of HIV-1 reverse transcriptase.

Althaus IW, Gonzales AJ, Chou JJ, Romero DL, Deibel MR, Chou KC, Kezdy FJ, Resnick L, Busso ME, So AG, et al.

J Biol Chem. 1993 Jul 15;268(20):14875-80.

31.

Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E.

Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, Romero DL, Palmer JR, Thomas RC, Aristoff PA, et al.

Biochemistry. 1993 Jul 6;32(26):6548-54.

PMID:
7687145
33.

U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.

Dueweke TJ, Poppe SM, Romero DL, Swaney SM, So AG, Downey KM, Althaus IW, Reusser F, Busso M, Resnick L, et al.

Antimicrob Agents Chemother. 1993 May;37(5):1127-31.

34.

Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E.

Althaus IW, Chou JJ, Gonzales AJ, Deibel MR, Chou KC, Kezdy FJ, Romero DL, Aristoff PA, Tarpley WG, Reusser F.

J Biol Chem. 1993 Mar 25;268(9):6119-24.

35.

Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors.

Vasudevachari MB, Battista C, Lane HC, Psallidopoulos MC, Zhao B, Cook J, Palmer JR, Romero DL, Tarpley WG, Salzman NP.

Virology. 1992 Sep;190(1):269-77.

PMID:
1382341
36.

Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication.

Romero DL, Busso M, Tan CK, Reusser F, Palmer JR, Poppe SM, Aristoff PA, Downey KM, So AG, Resnick L, et al.

Proc Natl Acad Sci U S A. 1991 Oct 1;88(19):8806-10.

Supplemental Content

Loading ...
Support Center